Introduction
Type I diabetes, which results from autoimmune destruction of pancreatic ␤ cells, is characterized by insulin deficiency. 1 Current treatment consists of multiple daily subcutaneous injections of long-and short-acting recombinant insulin analogues. 2 Delivery of insulin by gene therapy represents an attractive alternative to protein replacement therapy by potentially providing a more convenient and cost-effective mode of delivery. Successful therapy will require that mature insulin be expressed from a site distinct from the physiologic site of insulin production and that its expression be regulated appropriately. 3 Insulin is naturally synthesized in ␤ cells as a pre-prohormone. 4 After the signal peptide is cleaved in the lumen of the endoplasmic reticulum, proinsulin conversion to insulin occurs in a multistep process within granules of the regulated secretory pathway. 4, 5 In this compartment, the combined action of two subtilisin-like pro-hormone convertases, PC2 and PC3, is responsible for excision of the C-peptide from the A-and B-chains, which are kept together by two disulfide bonds. 5 Mature insulin, together with the C-peptide and the processing machinery, is then retained in the late endosomes under the ␤ cell membrane. Blood glucose enters the ␤ cell via the GLUT-2-specific transporter and is then converted to glucose-6-phosphate (G-6-P) by glucokinase (GK). G-6-P alters the ATP:ADP ratio, which inhibits the K ATP channel, resulting in membrane depolarization and the release of insulin-filled granules into circulation. 6 The liver has many features that make it a desirable target for ectopic insulin expression. 7 It is easily accessible -viral vectors can efficiently enter hepatocytes after intravenous administration -and is capable of mediating the production and release of therapeutic proteins into the systemic circulation. [8] [9] [10] Interestingly, both the liver and pancreas emerge from the ventral foregut endoderm and are specified at about the same time during embryonic development. While liver and pancreatic buds express different transcription factors and specialized gene products, some gene products are common to both tissues, 11 including some of the essential factors in glucose metabolism, such as GLUT-2 and GK. 12 In addition, a K ATP channel similar to that expressed in pancreas is expressed in hepatocytes and involved in the regulation of cell volume and DNA synthesis. 13 Finally, several reports point to the ability of some liver-derived cell lines transduced with an insulin gene to store and release insulin in response to a glucose stimulus via either the GLUT-2-GK 14 or an alternate pathway. 15 One system for achieving control of recombinant insulin secretion is through pharmacological induction of insulin transcription. A number of systems based on modulating transgene expression have been devised. These systems are all based on the use of an engineered transcription factor whose activity is controlled by a small molecule drug, and a target gene whose expression is driven by the regulated transcription factor. We have previously described a transcriptional switch based on rapamycin, a small molecule natural product that mediates the formation of heterodimers between the immunophilin FKBP and the lipid kinase homologue FRAP. By fusing FKBP domains to a DNA-binding domain called ZFHD1 and the rapamycin-binding domain of FRAP to a transcriptional activation domain from the p65 subunit of human NF-B, reconstitution of a functional transcription factor and expression of a target gene is made dependent on the presence of rapamycin. 16 In this report we evaluate the use of somatic gene transfer in achieving physiologic and pharmacological control of insulin secretion from liver and muscle.
Results

Mature insulin secretion by 293 cells infected with Ad-CMV-hIns-wt, -hIns-M3, -PC2 and -PC3
To identify the optimal approach for generating mature, exogenously expressed insulin, adenoviral vectors were created that constitutively express human proinsulin (hIns-wt), furin-cleavable proinsulin (hIns-M3), PC2 or PC3. 293 cells were then infected with the various vectors, either alone or in combination, and the level of mature insulin secreted in the medium determined 24 h later ( Figure 1 ). Infection with hIns-wt, with or without PC2, resulted in low-level secretion of mature insulin. Higher levels of processed hormone from hIns-wt were progressively obtained by co-administration of PC3, or PC2 and PC3, respectively. However, the highest levels of mature insulin were produced by infection with the hIns-M3 vector and these levels were not significantly increased by co-infection with PC2 or PC3. Total insulin levels (ie processed and unprocessed) were measured for each sample and no significant differences were detected (data not shown). This indicates that the lower levels of mature hormone derived from hIns-wt are due to inefficient processing, rather than lower levels of expression.
Overall, these data demonstrate that the most efficient production of mature insulin from 293 cells is obtained by exploiting endogenous furin to process an appropriately modified pro-insulin, although co-expressing PC2 and PC3 does enhance the production of mature insulin from hIns-wt.
Western blot and NH 2 -terminal sequence analysis of recombinant insulin secreted by 293 cells infected with the viral vectors
To biochemically analyze the insulin produced from adenovirus-infected 293 cells, secreted insulin was purified from medium using immuno-affinity chromatography. The proteins were then fractionated by SDS-PAGE and blotted with an anti-insulin polyclonal antibody (Figure 2a and b) . For reference, a commercial sample of mature insulin was analyzed (Figure 2a and b, lane 1). Cells infected with virus expressing hIns-wt produced a single, more slowly migrating band which corresponds to unprocessed proinsulin, as determined by its molecular weight and NH 2 -terminal sequence (Figure 2a and b, lane 2). Co-infection of hIns-wt and PC2 yielded proinsulin and two additional bands whose molecular weight is intermediate between that of the pro-and mature hormones ( Figure 2b, lane 3) . These are likely to represent species in which cleavage has only occurred at one of the two sites. 17 In contrast, co-infection with hIns-wt and PC3 produced a band that co-migrates with proinsulin and a second, somewhat less intense band that co-migrates with mature insulin (Figure 2b, lane 4) . Finally, infection with the hIns-M3 vector encoding furin-cleavable insulin produced proinsulin-and mature insulin-sized bands in approximately equal proportions (Figure 2a, lane 3) . NH 2 -sequencing of the lower band identified two independent sequences that correspond to the insulin A and B chains. These results confirm that co-expression of proinsulin and PC3, or expression of furin-cleavable proinsulin, leads to the production of mature insulin from 293 cells. In the case of furin-cleavable pro-insulin, the~50% yield of the mature protein is consistent with previous reports. 18, 19 Stimulation of insulin receptor tyrosine phosphorylation by virus-produced recombinant insulin We next determined whether the insulin produced from infected cells was biologically active. CHO cells overexpressing the insulin receptor (-IR) were either untreated, treated with 100 ng/ml of commercial insulin, or treated with equivalent amounts of protein immunopurified from cells infected with hIns-wt or hIns-M3 vectors. Transfected CHO cells not expressing the insulin receptor were used as controls (CHO-neo cells). Cell lysates were fractionated by SDS-PAGE and blotted with either an anti-phosphotyrosine (-PY) or -IR antibody 
Furin expression in various murine tissues
Our in vitro results suggested that the furin-cleavable form of proinsulin could give rise to high-level production of mature and biologically active insulin. To determine which tissues would be good targets for in vivo Gene Therapy expression, based on their ability to efficiently process the furin-cleavable form of proinsulin, the level of furin expression in various mouse tissues was evaluated. Tissue lysates were separated by SDS-PAGE, transferred to a nitrocellulose filter and blotted with an anti-furin antibody (Figure 2d ). The highest concentration of the protease was detected in liver and colon, with low or undetectable levels present in muscle and other tissues examined. These data indicate the particular suitability of liver as a target tissue for expression of insulin from a furin-cleavable precursor.
High-level expression of insulin from liver following in vivo vector transduction
We next assessed the ability of these vectors to produce insulin in vivo and thereby regulate glucose levels. To more easily assess the effects of insulin expression on glucose metabolism, mice were made diabetic by intraperi- mice was mock infected in each case. Blood glucose (BG) and mature serum insulin levels were then measured serially during the entire study period of 28 days.
The most rapid and robust expression of mature insulin was seen following i.v. administration of vector expressing furin-cleavable proinsulin (Figure 3a , hatched bars). Two days after transduction, insulin levels were > 4000 pM/l. As expected from the in vitro results, coadministration of vectors encoding PC2 and PC3 did not increase these expression levels. Elevated serum insulin was accompanied by a dramatic decrease in BG relative to the control group. Also in agreement with the in vitro studies, more modest levels of mature insulin were seen after administration of the hIns-wt vector to liver ( Figure  3a , open bars). At the peak 4 days after vector administration, insulin levels were~10% those seen in mice transduced with the furin-cleavable insulin vector, though these levels were still sufficient to significantly reduce BG levels. Co-administration of vectors encoding PC2 and PC3 did not increase expression of mature insulin.
More modest expression levels of mature insulin were obtained after viral transduction of muscle (Figure 3b ). Levels did not peak until 14 days after vector administration and were lower with the hIns-wt vector, with somewhat higher levels of insulin being obtained following transduction with the furin-cleavable insulin vector. In both cases and as seen in liver, expression levels were not increased by co-administration of vectors encoding PC2 and PC3. Overall however, these results indicate that high-level expression of insulin can be achieved by administration to the liver of a vector encoding a furincleavable form of proinsulin.
Expression of insulin from liver is constitutive
We next determined whether insulin secretion from transduced livers could be triggered by a blood glucose increase. Diabetic mice received i.v. 3 × 10 10 particles of either a mock vector, or adenoviral vectors constitutively expressing hIns-wt or hIns-M3, 4 days later were administered with 0.5 g/kg of glucose in saline and BGs and insulin levels were evaluated (data not shown). The same glucose challenge was performed on non-diabetic mice. BG levels were increased 2 min after the sugar load and decreased to normal levels after 120 min in both non-diabetic and insulin vector-treated diabetic mice, but persisted at high levels in the mock-treated diabetic animals. Moreover, insulin levels in the hIns-wt and hIns-M3 animals were stably elevated before, during and after the glucose challenge, indicating that the BG decrease in these groups was due to constitutive high levels of circulating insulin, rather than to a glucose-induced peak in hormone secretion. Despite low blood glucose levels in all animal groups administered vectors via tail vein, insulin secretion was sustained over time, leading to severe hypoglycemia.
Subcellular localization of insulin in transduced livers
In order to evaluate the subcellular localization of insulin in transduced hepatocytes, we performed immunoelectron microscopy on livers of mice 3 days after infection with either hIns-wt or hIns-M3 vectors. Figure 4 shows the subcellular localization of recombinant insulin in the liver of a mouse administered hIns-wt. As determined by electron microscopy, approximately 5% of the hepatocytes exhibited positive insulin labeling, with the majority of labeling being closely associated with the Golgi compartment. Immunogold particles were frequently found either within the lumen of Golgi vacuoles or attached to the Golgi membrane. Small Golgi vesicles containing many gold particles were also observed near the Golgi area. In hepatocytes containing insulin-positive Golgi apparatus, large, insulin-positive vacuoles or granules were never observed. No specific labeling was found in other organelles such as nuclear matrix, mitochondria and lysosomes, and no labeling was detected in bile canaliculi. Similar results were obtained following immunoelectron microscopy of liver transduced with hIns-M3 (data not shown). The lack of detectable insulin-containing granules is consistent with the observation that insulin is secreted constitutively from transduced liver.
Rapamycin-inducible expression of insulin from the liver of SZ-treated mice administered with adenoviral vectors
The lack of physiologically responsive insulin secretion from transduced liver, which led to severe hypoglycemia, prompted us to explore alternative means of regulating insulin expression. To test the effects of controlling insulin expression pharmacologically, we used the rapamycin-based regulation system to control transcription of the furin-cleavable proinsulin gene introduced into diabetic nude mice by tail vein injection. Separate adenoviral vectors expressing the rapamycin-regulated transcription factor (Ad-CMV-TF1) and a hIns-M3 transgene downstream of 12 binding sites for the regulated transcription factor (Ad-Z12-hInsM3) were co-administered, at various doses, in a 1:1 ratio. A control group received the Ad-CMV-TF1 vector alone.
Four days after vector administration, animals were dosed with rapamycin (1 mg/kg i.p.) and BGs were monitored closely (Figure 5a ). BGs decreased in all mice except the control group, with the more profound decreases occurring in mice which received the highest doses of vector. The decrease in BGs was evident 12 h after drug administration and persisted for 48-72 h after which the animals returned to their pre-induction hyperglycemic state. A similar response was seen following a second administration of 1 mg/kg rapamycin. Subsequent administration of decreasing doses of rapamycin Gene Therapy
Figure 5 Rapamycin-inducible insulin expression from the liver of SZtreated mice transduced with adenoviral vectors. (a) Blood glucose profile of diabetic mice administered with various doses of rapamycin and of the dual vector system at 1:1 ratio, containing hIns-M3. The effect on blood glucose of the secretion of human insulin is proportional to the dose of recombinant virus delivered and of rapamycin administered i.p. (b) Kinetics of insulin secretion from engineered livers upon rapamycin administration. A single dose of 1 mg/kg of rapamycin was given intraportally to the mice that received various doses of the dual adenoviral vectors. The peak secretion is proportional to the viral dose delivered. The control group received 1 × 10 11 particles of Ad-CMV-TF1. For the other groups, the total number of particles/mouse administered at 1:1 ratio between the two vectors is shown.
led to more modest decreases in BGs. Circulating mature insulin levels were measured following an induction with 1 mg/kg of rapamycin (Figure 5b ). Insulin levels peaked by 15 h and returned to basal levels by 40 h after drug administration, with the level of insulin secreted being proportional to the dose of vector administered. Thus transcriptional control of insulin expression using rapamycin enabled dose-dependent induction of circulating insulin levels that led to a transient correction of hyperglycemia in diabetic mice.
Discussion
The limited availability of islets for transplantation and the potential elimination of transplanted cells by the immune system make engineered, surrogate ␤ cells a desirable alternative treatment for type I diabetes. Such cells should be capable of glucose-regulated insulin secretion, potentially requiring an efficient insulin synthesis and processing machinery, a glucose sensor and the ability to store the recombinant hormone in granules to be quickly released upon an increase in blood sugar concentration. Several efforts have been initiated to engineer human insulin-secreting cell lines derived from islets for this purpose. 20, 21 The goal of this study was to engineer hepatocytes and muscle cells, traditional targets for vector-mediated production of secreted proteins, into surrogate ␤ cells. In particular, we investigated whether autoregulation of insulin expression could be achieved in hepatocytes, based on their hypothetical ability to store insulin once transduced with a vector encoding for the hormone and release it upon a glucose stimulus. We also investigated the feasibility of pharmacological regulation of insulin expression as a way to reconstitute basal insulin secretion.
Hepatocytes are appealing candidates as surrogate ␤ cells if supplied with the appropriate factors necessary to synthesize and secrete insulin. 7 They express the same pivotal components of the glucose sensor as islets, GLUT-2 and GK. 12, 22 In addition, independent studies aimed at in vivo insulin expression in liver using viral vectors show that biologically active insulin can be secreted by hepatocytes. [23] [24] [25] [26] [27] [28] More interestingly, a few groups engineered hepatoma cell lines with the insulin cDNA and claim that these cells are able to store and release the hormone upon a glucose stimulus.
14, 15 We therefore investigated whether supplying the liver of diabetic mice with viral vectors encoding insulin and its processing apparatus could result in efficient, glucose-regulated secretion of the hormone.
We produced adenoviral vectors encoding hIns-wt, hIns-M3, PC2 and PC3, which were used to begin the reconstitution of a regulated secretory pathway in non-␤ cells. Our in vitro studies confirmed that mature insulin could be formed from proinsulin cleavage through the action of any of the two proteases, although PC3 seems more efficient. The combined action of the two proteolytic enzymes on proinsulin results in higher levels of processed hormone than their separate action. These findings are in agreement with previous reports. 17, [29] [30] [31] Nevertheless in the absence of a regulated secretory pathway, the action of the endogenous furin on the hIns-M3 molecule leads to more efficient processing and is independent of the addition of the proteases. We also characterized the protein products secreted by 293 cells transduced with our vectors using Western blot and aminoterminal sequence and showed their ability to induce insulin receptor transphosphorylation.
In order to understand which combination of vectors results in efficient proinsulin processing in vivo and whether insulin can undergo storage and glucose-dependent release from liver, we targeted our vectors to the liver and, for comparison, to the muscle in a chemically induced model of type I diabetes. 32 Introducing the hInswt adenovirus into muscle of diabetic mice resulted in normalization of the BGs only when the PC2 and PC3 are added. This confirms our finding in 293 cells and supports the hypothesis that in a cell not committed to intense protein synthesis and secretion, the addition of PC2 and PC3 is required for efficient insulin processing. Mature insulin was not detected with the specific RIA in this group despite partial correction of hyperglycemia. This may be due to the secretion of biologically active intermediates undetected by the RIA specific for the fully processed product. Transduction of muscle with the hIns-M3 vector resulted in correction of the BGs and increase in serum insulin.
Hepatocytes of diabetic mice were targeted with vectors by tail vein injection. We detected a decrease in BGs and elevation of mature human insulin levels 4 days after administration of vector encoding hIns-wt with or without the pancreatic proteases. Surprisingly liver, unlike muscle, is able to process proinsulin to a significant extent and secrete mature hormone. This is in agreement with a previous report, which describes normalization of BGs in hepatectomized diabetic rats administered with retroviruses encoding rat proinsulin. 23 We could not detect endogenous PC2 or PC3 expression in liver, although we found higher levels of furin in the liver than in the muscle. Furin, overexpressed in cell culture, has been reported to cleave the A and B chains from the Cpeptide. 30, 31 We therefore speculate that this or a similar enzymatic activity in liver is responsible for proinsulin processing.
In liver, proinsulin cleavage, and therefore mature insulin secretion, was not significantly increased by the addition of proteases. The fact that vector encoded PC2 and PC3 functioned in vitro suggests that the lack of an effect in liver is not due to inadequate transgene expression. One hypothesis is that PC2 and PC3 activities, normally present in the mature granules of the ␤ cells at pH 5.5, 33 are reduced in a cell containing the constitutive secretory pathway. While in muscle the effect on proinsulin of the two subtilisin-like proteins is evident due to the lack of similar enzymes, in liver the presence of efficient proteases active in the constitutive secretory pathway may mask the effect of exogenous PC2 and PC3. The co-presence in the targeted hepatocytes of the insulin-M3 molecule containing furin cleavage sites and of the enzymatic activities required for processing, explains the fastest and most robust secretion of insulin observed after hIns-M3 administration to the liver. This may also explain why hIns-M3 conversion was independent of the action of PC2 and PC3.
These data demonstrate that hepatocytes are able to secrete mature, functional recombinant insulin in vivo. Based on the results from previous studies demonstrating glucose-regulated insulin secretion from hepatoma cell lines, 14, 15 we tested the ability of engineered hepatocytes in vivo to store the hormone and release it upon a glucose stimulus (properties that are also retained by the intestinal K cells). 34 Our immuno-electron microscopy data showed that the protein is abundantly present in the Golgi lumen as expected for a secreted protein. However no electron-dense granules were detected, suggesting that the hormone is directly released outside the cells following its synthesis and processing. The absence of gold particles in the bile canaliculi in addition suggests that hepatocytes secrete the hormone mainly in the bloodstream. In agreement with the absence of a storage compartment for the hormone in transduced hepatocytes is the continuous release of insulin from these livers. This is suggested by the persistent hyperinsulinemia, despite profound hypoglycemia, found in treated diabetic animals. In addition, hyperglycemia triggered by an i.v. glucose load does not result in a quick release of insulin in corrected diabetic animals, confirming that the hormone is constitutively secreted from transduced livers.
We conclude that, although the liver possesses many attractive features for use as factory for manufacture of insulin following somatic gene transfer, it is not able to provide the desired physiologic regulation of the gene in response to blood glucose. Based on this finding, we initiated the testing of alternative methods for obtaining controlled expression of the protein. Regulation of insulin expression can theoretically be achieved through physiologic and pharmacological cues. Although, glucoseinduced insulin expression is preferable (ie physiologic regulation), the current efforts are limited to the use of promoters that are glucose-sensitive. [25] [26] [27] [28] 35 In this case, exogenous insulin expression from the vector is induced several hours after the hyperglycemic peak, because of the delay due to transcription and translation of the insulin product. A similar interval of time is required to reverse hormone expression to negligible levels upon return to a normoglycemic status, due to the requirement to suppress transcription that is mediated by inducible transcription factors and to the half-life of the RNA. The net result is an induction of insulin that is delayed beyond the peak of BG and persists during post-prandial episodes of hypoglycemia. In humans, metabolic control using this approach would not be feasible exposing patients to dangerous hyperglycemic and hypoglycemic fluctuations. Attempts at obtaining physiologic control of insulin secretion either using cells equipped with the ability to store the recombinant hormone and release it upon a glucose-stimulus 34 or converting liver cells into ␤ cells, 36 are promising but preliminary. Several inducible systems for pharmacological control of gene expression have been created. 37, 38 Most of these systems control gene expression at the transcriptional level, although we recently described a novel approach to control the secretion of a recombinant product stored in the endoplasmic reticulum upon a pharmacological cue. 19 In this study, we tested the ability of the rapamycin inducible transcription system 16 to drive regulated expression of insulin following adenoviral gene transfer to liver. The different components of this system have been successfully delivered via viral vectors to murine 39 and primate muscle 40 and transgene expression was demonstrated to be inducible and dose-dependent upon rapamycin administration, as well as reversible after its withdrawal. Here we obtain similar results using rapamycin induction to regulate insulin expression from the liver of diabetic mice transduced with adenoviral vectors. Little expression was observed in the absence of rapamycin as shown by the hyperglycemic status of mice transduced with the vectors. Induction of insulin expression occurred within 12 h, as expected in a system where regulation of expression is achieved at the transcriptional level.
Transcriptional regulation of insulin expression, either pharmacological or physiologic, will not simulate the kinetics of post-prandial acute peak insulin secretion. Nevertheless, pharmacological (but not glucose-) regulated transcription may be a feasible way to obtain therapeutic baseline levels of the hormone in a gene therapy setting. In many ways transcriptional regulation can replace and potentially improve upon the requirement of long acting insulin. This, however, would have to be supplemented by administration of short acting insulin or by pharmacologically regulated secretion of recombinant insulin Gene Therapy already synthesized and stored in subcellular compartments. 19 The goal of creating a genetically engineered surrogate ␤ cell is indeed complicated. Our study indicates that engineering of hepatocytes to result in physiologic regulation of insulin secretion is indeed more complex than suggested. Pharmacological regulation of insulin transcription and/or secretion appears feasible. Whether this genetic strategy can be assembled into a therapeutic modality that is safer and more effective than insulin replacement therapy is worth evaluating in additional studies.
Material and methods
Adenoviral vector construction
The human proinsulin (-hIns-wt), PC2 and PC3 coding sequences were PCR amplified from a human pancreas cDNA sample (Clontech, Palo Alto, CA, USA). To create hIns-M3, hIns-wt was modified by site-directed mutagenesis to create recognition sequences for the protease furin at the B-C and C-A peptide junctions and to mutate His at amino acid B10 to Asp. 18 pAd-CMV-hInswt and -M3 were created by inserting the appropriate cDNA downstream of the CMV enhancer/promoter (from pCEP4; Invitrogen, Carlsbad, CA, USA) and a chimeric intron (from pCAT3 Basic; Promega, Madison, WI, USA) and upstream of the SV40 late 3'UTR (from pCAT3 Basic). These expression cassettes were then cloned into pAd-link (Vector Core, Institute for Human Gene Therapy, University of Pennsylvania, PA, USA) to create pAd-CMV-hIns-wt and pAd-CMV-hIns-M3. pAd-Z12-hIns-M3 was created by exchanging hGH with hIns-M3 in the adenoviral construction vector carrying hGH previously described. 39 Similarly, the hPC2 and hPC3 coding sequences were cloned into the pAd-CMV-link backbone (Vector Core, Institute for Human Gene Therapy, University of Pennsylvania). The pAd-CMV-transgene plasmids were used for co-transfection of 293 cells (ATCC, Manassas, VA, USA) with ClaI digested H5.010CMVEGFP viral backbone containing deletions in map units 1-9 of the E1 region and in E3 region (sub360) to create adenoviruses by homologous recombination. Recombinant plaques were initially isolated through green/white selection 41 and confirmed by restriction enzyme analysis of Hirt DNAs and RIA for detection of insulin expression. The positive plaques were purified and grown up in 293 cells for CsCl gradient purification. 42 Ad-CMV-TF1 was described previously. 39 Production, purification and RIA/ELISA analysis of recombinant insulin from 293 cells infected with adenoviral vectors Subconfluent 293 cells were cultured in Dulbecco's modified Eagle medium (DMEM) added with 10% fetal bovine serum (FBS) and 100 U/ml of penicillin-streptomycin at 37°C in 5% CO 2 . Serum-free DMEM was added and the cells were then infected with 1 × 10 3 particles of each adenoviral vector/cell. Medium was collected after 24 h and assayed using an RIA specific for mature human insulin (Linco Research, St Charles, MO, USA; assay performed by the Diabetes Research Center of the University of Pennsylvania, PA, USA) or an ELISA able to detect both C-peptide and proinsulin (Mercodia-ALPCO, Windham, CT, USA).
